Profound Medical Picks Its President For CEO — Arun Menawat Will Stay As Executive Chairman
The CEO handoff is scheduled for January 15, 2027, alongside a permanent finance chief and revised board pay.
Profound Medical, which makes MRI-guided ultrasound devices that destroy diseased tissue without incisions, picked President Richard R. Fabian to succeed as CEO on January 15, 2027. The board approved the plan on November 5, with current CEO Arun Menawat moving to executive chairman, according to an SEC filing made Thursday.
An Ultrasound Executive Takes Over
Fabian will keep the president title and attend board meetings as a non-voting observer. Menawat will retain his director seat and receive $225,000 in annual cash pay plus a yearly stock award valued at $375,000 at grant; his outstanding stock units and options will remain governed by their existing terms.
Fabian became president on September 1, 2026. He ran FUJIFILM Sonosite's global point-of-care ultrasound business as president and CEO from 2017 to June 2026, and held executive roles in Philips Healthcare's imaging and image-guided therapy operations from 2002 to 2016. At STERIS, his earlier work spanned finance and operations.
Profound's TULSA-PRO system treats prostate cancer and benign prostate enlargement by destroying tissue across the prostate or in a physician-selected region. Its Sonalleve system treats uterine fibroids and certain bone tumors. The devices work with MRI scanners supplied by Philips, Siemens and GE Healthcare.
Physicians at hospitals and imaging centers buy its equipment, while patient treatments generate recurring sales of single-use devices and related services. In 2025, the United States accounted for about 76% of revenue, the EU for 5% and Asia for 19%.
Sobczyk Gets The Permanent Finance Role
Matthew Sobczyk became permanent CFO on November 5. He had held the interim job since August 14, 2026, after serving as corporate controller from March 2023 to August 2026.
Sobczyk joined Profound in May 2017 as manager of accounting and reporting, then became assistant corporate controller in March 2021. Before joining, he spent over a decade in accounting, audit and advisory work at Ernst & Young and MNP.
His annual salary is C$300,000, with a discretionary bonus targeting 50% of salary. He will receive a one-time award of 5,000 restricted share units—rights to receive shares under the award's terms—and 5,000 share options, and is eligible for annual long-term incentive awards.
A New Director And Board Pay
Jason Mills filled the board seat vacated by Cynthia Lavoie on November 5, effective immediately. The company said Lavoie's resignation did not stem from a disagreement with Profound. Mills will serve through the 2027 annual shareholder meeting and until a successor is elected and qualified.
Starting January 1, 2027, non-employee directors will receive a $55,000 annual cash retainer and qualify for yearly equity awards worth $110,000, vesting after 12 months.
The audit committee chair will receive an additional $20,000 annually, and the human resources and corporate governance committee chair an additional $12,000. Committee members will receive $5,000 a year for each committee they serve on.
The board's revised pay policy takes effect January 1, 2027; Fabian's CEO handoff follows on January 15, 2027.
Sources
- 8-K Filing — Profound Medical Corp. (PROF) — SEC EDGAR
- Profound Medical to Participate in the Stifel 2026 — globenewswire.com